Literature DB >> 2499273

Dietary treatment of hyperlysinaemia.

J W Gregory1, N Beail, N A Boyle, C Dobrowski, P Jackson.   

Abstract

We describe the lysine restricted, dietary management of three out of four siblings who were identified as having hyperlysinaemia. The diets, started in the neonatal period, were maintained for varying periods with unpredictable success. The propositus, who was not treated, was diagnosed at the age of 5 years, by which time he was already severely handicapped, presumably because of his metabolic disorder. Tentative recommendations are put forward for the management of this seemingly rare disorder. Mild chronic ammonia toxicity may be a factor in the pathogenesis of this condition.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2499273      PMCID: PMC1792052          DOI: 10.1136/adc.64.5.716

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  6 in total

1.  Hyperlysinaemia. Harmless inborn error of metabolism?

Authors:  H H van Gelderen; H L Teijema
Journal:  Arch Dis Child       Date:  1973-11       Impact factor: 3.791

2.  Hyperlysinemia associated with retardation.

Authors:  H Ghadimi; V I Binnington; P Pecora
Journal:  N Engl J Med       Date:  1965-09-30       Impact factor: 91.245

3.  A case of hyperlysinemia: biochemical and clinical observations.

Authors:  M D Armstrong; M Robinow
Journal:  Pediatrics       Date:  1967-04       Impact factor: 7.124

4.  Further studies of hyperlysinemia.

Authors:  N C Woody; J Hutzler; J Dancis
Journal:  Am J Dis Child       Date:  1966-12

5.  Hyperlysinemia without clinical findings.

Authors:  I Ozalp; A Hasanoğlu; E Tunçbilek; K Yalaz
Journal:  Acta Paediatr Scand       Date:  1981-11

6.  The prognosis of hyperlysinemia: an interim report.

Authors:  J Dancis; J Hutzler; M G Ampola; V E Shih; H H van Gelderen; L T Kirby; N C Woody
Journal:  Am J Hum Genet       Date:  1983-05       Impact factor: 11.025

  6 in total
  4 in total

1.  Neurochemical evidence that lysine inhibits synaptic Na+,K+-ATPase activity and provokes oxidative damage in striatum of young rats in vivo.

Authors:  Bianca Seminotti; Carolina Gonçalves Fernandes; Guilhian Leipnitz; Alexandre Umpierrez Amaral; Angela Zanatta; Moacir Wajner
Journal:  Neurochem Res       Date:  2010-10-27       Impact factor: 3.996

2.  Antenatal diagnosis of inborn errors of metabolism.

Authors:  J W Gregory
Journal:  Arch Dis Child       Date:  1992-01       Impact factor: 3.791

3.  Characterization and structure of the human lysine-2-oxoglutarate reductase domain, a novel therapeutic target for treatment of glutaric aciduria type 1.

Authors:  João Leandro; Susmita Khamrui; Chalada Suebsuwong; Peng-Jen Chen; Cody Secor; Tetyana Dodatko; Chunli Yu; Roberto Sanchez; Robert J DeVita; Sander M Houten; Michael B Lazarus
Journal:  Open Biol       Date:  2022-09-21       Impact factor: 7.124

4.  Genetic basis of hyperlysinemia.

Authors:  Sander M Houten; Heleen Te Brinke; Simone Denis; Jos Pn Ruiter; Alida C Knegt; Johannis Bc de Klerk; Persephone Augoustides-Savvopoulou; Johannes Häberle; Matthias R Baumgartner; Turgay Coşkun; Johannes Zschocke; Jörn Oliver Sass; Bwee Tien Poll-The; Ronald Ja Wanders; Marinus Duran
Journal:  Orphanet J Rare Dis       Date:  2013-04-09       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.